Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
NKGen Biotech ( (NKGN) ) just unveiled an announcement.
On February 20, 2026, NKGen Biotech, Inc. and its subsidiary NKGen Operating Biotech, Inc. entered into a fourth amendment to their secured promissory note with AlpineBrook Capital GP I Limited, adding a further $343,000 in funding. This amendment increased the principal on the note to $27,101,106 and specified that interest on the new tranche accrues from February 20, 2026, underscoring NKGen’s continued dependence on incremental debt financing to fund its ongoing operations.
The additional capital from AlpineBrook represents another short-term liquidity boost following several amendments to the original January 2026 note. This pattern of successive funding increases may signal both the company’s near-term cash needs and AlpineBrook’s ongoing willingness to provide credit support, developments that are likely to be closely watched by investors and other stakeholders tracking NKGen’s financial runway.
More about NKGen Biotech
NKGen Biotech, Inc. is a biotechnology company focused on developing cell-based therapies, with operations conducted through its subsidiary NKGen Operating Biotech, Inc. The company operates in the life sciences sector and relies on external financing arrangements to support its research, development, and corporate activities.
Average Trading Volume: 6,883
Technical Sentiment Signal: Sell
Current Market Cap: $7.84M
For an in-depth examination of NKGN stock, go to TipRanks’ Overview page.